Clinical Issues in Rheumatoid ArthritisDiscussions and Debates on the Evolving Roles of Targeted Synthetic DMARDs
Additional Abstracts From the 2017 American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting.
November 2017; San Diego, California.
Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice.
Anderson J, et al. Arthritis Care Res (Hoboken). 2012;64(5):640-647.
Methotrexate and rheumatoid arthritis: current evidence regarding subcutaneous versus oral routes of administration.
Bianchi G, et al. Adv Ther. 2016;33(3):369-378
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.
Cohen SB, et al. Ann Rheum Dis. 2017;76(7):1253-1262.
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.
Dougados M, et al. Ann Rheum Dis. 2017;76(1):88-95.
Long term safety of filgotinib in the treatment of rheumatoid arthritis: week 84 data from a phase 2b open-label extension study.
Genovese MC, et al. Arthritis Rheumatol. 2017;69 (suppl 10). Abstract 1909.
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
Fleischmann R, et al. Lancet. 2017;390(10093):457-468.
Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group.
Fleischmann R, et al. Clin Rheumatol. 2017;36(1):15-24.
Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies.
Fleischmann R, et al. RMD Open. 2017;3(2):e000491.
Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis.
Genovese MC, et al. Rheumatology. 2018;57(5):900-908.
Upadacitinib (ABT-494) in patients with active rheumatoid arthritis and inadequate response or intolerance to biological DMARDs: a phase 3 randomized, placebo-controlled, double-blind study of a selective JAK-1 inhibitor.
Genovese MC, et al. Arthritis Rheumatol. 2017;69(suppl 10). Abstract 10L.
Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2).
Kavanaugh A, et al. Ann Rheum Dis. 2017;76(6):1009-1019.
No effect of baseline serum CRP levels on clinical efficacy parameters in rheumatoid arthritis patients treated with filgotinib: post hoc analysis from two phase 2B studies.
Kavanaugh A, et al. Arthritis Rheumatol. 2017;69 (suppl 10) Abstract 537.
Time to achieve moderate/low disease activity and remission in RA patients on baricitinib compared to adalimumab, methotrexate, and placebo.
Keystone EC, et al. Arthritis Rheumatol. 2017;69 (suppl 10). Abstract 513.
Peficitinib, a JAK inhibitor, in the treatment of moderate-to-severe rheumatoid arthritis in patients with an inadequate response to methotrexate.
Kivitz AJ, et al. Arthritis Rheumatol. 2017;69(4):709-719.
Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year.
Kremer JM, et al. Arthritis Rheum. 2011;63(3):609-621.
Cycling versus swapping in patients with rheumatoid arthritis with an inadequate response to at least one tumor necrosis factor alpha inhibitor: a systematic review and meta-analysis of observational study.
Lopez-Olivo MA, et al. Arthritis Rheumatol. 2017;69(suppl 10):Abstract 2483.
McInnes IB, Schett G. Lancet. 2017;389(10086):2328-2337.
Scott IC, et al. Drug Saf. 2018 Mar 2. [Epub ahead of print].
Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).
Westhovens R, et al. Ann Rheum Dis. 2017;76(6):998-1008.
Using Imaging to Improve Patient Outcomes
Discussions and Debates on the Evolving Roles of Targeted Synthetic DMARDs
Improved Diagnostic and Management Strategies
Long-Term Management Strategies to Improve Patient Outcomes
Evidence-Based Strategies for Improved Patient Outcomes
Evolving Strategies for Diagnosis and Long-Term Management
Treating to Target, IL-6-Directed Therapies, and Evolving Management Algorithms
Evolving Treatment Algorithms and Expert Perspectives on Biosimilars
Pathophysiology to the Management of Moderate-to-Severe Disease
Targeting Immune Dysregulation and Delivering Comprehensive Care
Translating Comprehensive Patient Evaluations Into Personalized Therapy
Looking Beyond Barriers to Optimize Therapy
New Perspectives on Targeting Remission and Individualizing Therapy
Using Imaging to Improve Patient Outcomes
Translating Pathophysiology into Targeted Treatments
Think You Know JAK?
An Interactive Experience Highlighting Recent Clinical Advances
Debates & Discussions on the Evolving Role of JAK Inhibitors
The Evolving Role of JAK Inhibitors
Unpacking the Evidence for Their Use Today and Tomorrow
Unlocking Novel Paths to Patient Care